{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:50:13Z","timestamp":1785700213314,"version":"3.56.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,2]]},"DOI":"10.7759\/cureus.113799","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:19Z","timestamp":1785697939000},"source":"Crossref","is-referenced-by-count":0,"title":["De Novo Lupus Anticoagulant-Positive Catastrophic Antiphospholipid Syndrome With Multiorgan Microvascular Failure: A Thrombotic Cascade Beyond Control"],"prefix":"10.7759","author":[{"given":"Mohd","family":"Laraib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo V","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, et al.. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018, 132:1365-71. 10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera R","year":"2018","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018, 92:1-11. 10.1016\/j.jaut.2018.05.007","journal-title":"J Autoimmun"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082274","article-title":"Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors","volume":"34","author":"Espinosa G","year":"2008","unstructured":"Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost. 2008, 34:290-4. 10.1055\/s-0028-1082274","journal-title":"Semin Thromb Hemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0031-7","article-title":"Catastrophic antiphospholipid syndrome","volume":"5","author":"Asherson RA","year":"2003","unstructured":"Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2003, 5:395-400. 10.1007\/s11926-003-0031-7","journal-title":"Curr Rheumatol Rep"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1177\/0961203310361489","article-title":"Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?","volume":"19","author":"Pierangeli SS","year":"2010","unstructured":"Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?. Lupus. 2010, 19:475-85.","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016, 15:1120-4. 10.1016\/j.autrev.2016.09.010","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014175","article-title":"Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients","volume":"63","author":"Cervera R","year":"2004","unstructured":"Cervera R, Asherson RA, Acevedo ML, et al.. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. 2004, 63:1312-7. 10.1136\/ard.2003.014175","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/515318-de-novo-lupus-anticoagulant-positive-catastrophic-antiphospholipid-syndrome-with-multiorgan-microvascular-failure-a-thrombotic-cascade-beyond-control","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:20Z","timestamp":1785697940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/515318-de-novo-lupus-anticoagulant-positive-catastrophic-antiphospholipid-syndrome-with-multiorgan-microvascular-failure-a-thrombotic-cascade-beyond-control"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.113799","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}